Clinical trialNo phase (not a drug trial)Unknown
Carbon Ion Radiotherapy for Recurrent Pancreatic Cancer Post Surgery
- Outcome
- Outcome unknown
- Phase
- No phase (not a drug trial)
- Status
- Unknown
- Study type
- Interventional
- Start
- 1 June 2021
- Listed end
- 31 December 2024
- Enrollment
- 49 participants
- Sites
- 1
- Primary outcomes
- local progression-free survival
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 26 April 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The aim of this study is to evaluate the toxicity and tolerance of carbon ion radiotherapy for recurrent pancreatic carcinoma post surgery
Detailed description public domain (ClinicalTrials.gov)
The carbon dose of 67.5 Gy equivalent in 15 fractions was delivered to clinical target volume (CTV). The dose limiting toxicity (DLT) was defined as CTCAE grade 3 or higher of non-hematological toxicity (G3). The acute and late toxicities, overall survival (OS), progression-free survival (PFS), local progression-free survival (LPFS) and distant metastasis-free survival (DMFS) were the endpoints.